Cabozantinib in High Grade Neuroendocrine Neoplasms

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

November 24, 2020

Primary Completion Date

July 31, 2026

Study Completion Date

March 31, 2027

Conditions
High Grade Neuroendocrine Neoplasms
Interventions
DRUG

Cabozantinib

Cabozantinib should be taken on an empty stomach (at least 1 hour before or 2 hours after eating) at the same time every day.

PROCEDURE

Blood for plasma biomarkers

Baseline, cycle 1 day 8, cycle 1 day 15, and day 1 of every cycle thereafter

PROCEDURE

Tissue biopsy

Baseline, before start of cycle 2, and time of progression

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Exelixis

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT04412629 - Cabozantinib in High Grade Neuroendocrine Neoplasms | Biotech Hunter | Biotech Hunter